Charles River Laboratories International (CRL) EBITDA Margin: 2009-2025
Historic EBITDA Margin for Charles River Laboratories International (CRL) over the last 17 years, with Sep 2025 value amounting to 13.32%.
- Charles River Laboratories International's EBITDA Margin rose 169.00% to 13.32% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.50%, marking a year-over-year decrease of 950.00%. This contributed to the annual value of 5.61% for FY2024, which is 933.00% down from last year.
- Per Charles River Laboratories International's latest filing, its EBITDA Margin stood at 13.32% for Q3 2025, which was up 37.25% from 9.70% recorded in Q2 2025.
- In the past 5 years, Charles River Laboratories International's EBITDA Margin registered a high of 19.26% during Q2 2022, and its lowest value of -16.73% during Q4 2024.
- For the 3-year period, Charles River Laboratories International's EBITDA Margin averaged around 10.23%, with its median value being 13.12% (2023).
- In the last 5 years, Charles River Laboratories International's EBITDA Margin spiked by 422bps in 2022 and then plummeted by 2,984bps in 2024.
- Quarterly analysis of 5 years shows Charles River Laboratories International's EBITDA Margin stood at 19.09% in 2021, then tumbled by 420bps to 14.89% in 2022, then plummeted by 178bps to 13.12% in 2023, then tumbled by 2,984bps to -16.73% in 2024, then spiked by 169bps to 13.32% in 2025.
- Its last three reported values are 13.32% in Q3 2025, 9.70% for Q2 2025, and 7.59% during Q1 2025.